|Shares Out. (in M):||0||P/E|
|Market Cap (in $M):||412||P/FCF|
|Net Debt (in $M):||0||EBIT||0||0|
Sign up for free guest access to view investment idea with a 45 days delay.
I am a bit late to the show on this one as it bottomed a couple months ago at about $16. I don’t usually look at companies this small but have intermittently checked on LCAV due to a history with the company and a relationship with the new CEO, Steve Strauss. So when I happened to see a ticker tape roll by with a print of LCAV under $20 I suspected there was a nice opportunity in an undervalued name with good management that I know. The stock has gotten killed in the last 6 months dropping from $50 to a low of $15.30 as growth ‘investors’ dumped the shares following a revenue restatement and an earnings miss. I’m not worried about either of those things and believe the underlying business is in good shape. The primary negative factors are macro in nature, which are certainly real, but do not warrant the drop.
LCA Vision is the largest corporate provider of laser vision
corrective surgery in the
LCAV is worth $30 a share versus the current price of $20.
Importantly, this value does not factor in any real improvement in the market
dynamics (increased penetration into the vast available market, etc) or capital
allocation opportunities (big share buyback) that could move the value further
north of $30.
The management team is why LCAV caught my eye on the tape. I have known Steve Strauss, the new CEO for about 8 years and respect him. I have only spoken to him about the business once since he took the job and that was in June when the price was about $45. However he has a long history in the vision correction industry with a six year stint on the board of Laser Vision Centers, which was acquired by TLCV in 2001 where he stayed on for awhile. Steve’s entire career has been in the healthcare field, most recently as President of MSO Medical, an obesity products company, before taking the top spot at LCAV. Steve is ambitious and driven, his personality and character make me think he will do whatever it takes to address any issues and operate the company with excellence. His long experience in the industry and familiarity with his most serious competitor, TLCV, will aid in that process. Importantly, Steve personally bought 5000 shares on December 12th at $18.55. This wasn’t an options exercise but an open market purchase. Over the last six months there have been six instances of insider buying and no sells, but this last example by the new CEO is the most telling in my mind. His total personal holdings are only 17k shares, but it is important to remember he has only been there a year and this is his first position at the top of a public company and this could be a substantial investment on his part.
Corrective eye surgeries are LCAV’s only business. As mentioned they provide two procedures, PRK and LASIK. PRK actually involves the removal of the epithelium of the cornea, its protective covering, which necessitates a protective contact be worn and a long recovery. LASIK merely peals back the epithelium so the laser can adjust the surface of the eye. The epithelial flap is then folded back down which allows a much faster recovery. The development of laser based procedures with the quicker recovery time resulted in lower customer reluctance. This was partially responsible for the explosion in corrective procedures in the late ‘90’s. Until recently LASIK still required an actual blade, a microkeratome, to create the epithelial flap. AMO’s Intralase system addresses this ickiness factor by using a laser to cut the flap. Using an Intralase system for the flap and an excimer laser for the actual reshaping means nothing actually touches the physical eye providing both increased accuracy and less customer reluctance. It is estimated that LCAV has 75% of its centers with Intralase capability, I assume that the rest will catch up soon. A full laser operation with a quick recovery and a higher customization component will likely further reduce the fear factor that has traditionally been an inhibitor.
The potential market for corrective procedures in the
The second historical inhibitor, cost, is also being
addressed. Costs per eye have dropped to a level that is more palatable to the
average consumer. Even more importantly, financing options have evolved
substantially. GE and Wells Fargo both provide third party financing through
LCAV, there is also an in house financing vehicle for those that don’t qualify
for third party financing. The result has been the migration of an eye procedure
from a $5000 out of pocket expenditure 8 years ago to something more like a car
purchase. The sticker price is still $1500 (roundabouts) per eye, but with the
financing it translates into a $60 a month payment to add to the car and credit
card. Not that I support this debt funded consumption style that fuels
Making laser eye procedures less fear laden and more
affordable is the key component of increased penetration. However, the industry
still needs to let people know about the progress via effective advertising.
Mom and pops have historically been unable to advertise well and have largely
been cash flow junkies that spend in good times and pull back in bad. The
corporate providers are the only operators with the scale to advertise
effectively. LCAV’s superior balance sheet position affords them the
flexibility to really advertise in a weak market environment and spread the
word about the fear and price reductions. As they continue to grow it is
increasingly feasible to leverage that scale with national advertising. Eventually
there will be a tipping point where the scale of national advertising can
quickly become a real competitive advantage in name recognition, especially
with the message of lower fear and cost. TLCV has more centers at the moment,
but LCAV has more potential and ability to grow as well as more inclination to
leverage the scale edge. The mom and pops will the real losers in such a
scheme. Even if top line procedure growth only tracks with population growth of
1.5-2% and penetration remains the same, market share capture from mom &
pops will be good for a much higher level of top line growth. High single
digits is all that I am modeling in to get to a $30 value, which I view as a
high probability proposition. Playing with the penetration numbers and the
potential national growth quickly moves the value close to recent peaks.
LCAV showed consistent year over year growth and 20%+ ROICs for the ‘01 to ‘06 time frame attracting a growthy shareholder base. When the 06 slowdown came and a resurgent TLCV begin making headlines LCAV missed earnings and the stock was crushed. Then there was a restatement of Deferred Revenue and the departure of the management team, causing another big down draft. As I have said neither of these issues worry me. The income numbers are fine although they did miss a quarterly consensus estimate. The deferred revenue issue was a technical one where the SEC made the company restate prior revenue numbers to reflect how they recognized income from the sale of separately priced extended warranties. Historically LCAV had only been deferring revenue for patients that they believed would receive future treatment under the warranty. Granted this provides some wiggle room, which is why the SEC said they had to defer all of the revenue received from selling these warranties. The total restatements totaled $18 million for 2006. This revenue goes into a reserve and will be realized on a straight line basis over the life of the warranty. The cash flow has already been realized and the GAAP accounting convention is the only change. Steve has said that the company is planning on ceasing the sale of these warranties anyway. This is a non-issue going forward. The earnings miss and an immaterial accounting change have spooked the growth investors that loved the story but didn’t value the fundamentals providing a lovely opportunity.
LCAV has no debt and a cash and investment balance that is 20% of the market cap. The company is very well positioned to ride out any near term market weakness and indeed to benefit from the resultant opportunity as weaker players are impacted. I believe LCAV shares are worth $30, more than 50% upside from current levels. This value is the middle of a multiples based value and a DCF value. This gives no credit for potential share buybacks or any aggressive assumptions on a shift in market fundamentals that allows for greatly increased penetration.
Comps for acquisition prices are hard to come by directly in
this field as most of them are small and private. TLCV has largely been built
on roll-ups, but mostly privately. In related fields and from what I can
surmise in this one, take out multiples run about 11-14 times operating income which
would be a high teens multiple on net income, about where these stocks have
traded historically. Going at the low end of that range and using 11 x’s on
2007 or 2008’s operating income, which I expect to be in the $45-46 million
range, and then adding back the non cash options expense of about $4 million, so
call it $50 total at 11 x’s, is $550 million in value for the operations. Then
add back in the cash and short term investments to get a total enterprise value
of $626 million. On diluted shares of 19.3 million outstanding this give $32.44
From a discounted cash flow perspective (which is of course
the yin to the multiples based value’s yang- two sides of the same coin) I use
$1.50 in free cash flow generation on a normal basis and assume that it will
grow in the 7-8% range for the next ten years with a 15 terminal multiple and a
10% discount rate to get $29 a share. I believe both of these values are fair
to low (the recent high was over $50) so I’ll split the difference and go with
$30 for a nice round number.
It is not necessary to factor in a working capital charge as I believe there is substantial room to reverse the WC trend of the last few years that has seen receivables turns drop from over 17 to 11 today. This is actually below TLCV for the first time and should remain flat to a source of cash going forward. If management were to take 75% of the cash balance and repurchase shares at today’s price than all else being equal the value would move up $5 to $35 a share. The company bought back $52 million in shares they retired in 2006, so there is a precedent. However, this was not under Steve and I am not sure he wouldn’t prefer to continue expansion as he has mentioned that the rates of returns on new stores are pretty hard to beat and is likely smarting at the repurchase of $50 million in stock at price well above where they are today, clearly a terrible capital allocation decision at the time with the shares above intrinsic value, although it would be a brilliant one today with the shares well below.Summary
|show sort by|
Are you sure you want to close this position LCA Vision?
By closing position, I’m notifying VIC Members that at today’s market price, I no longer am recommending this position.
Are you sure you want to Flag this idea LCA Vision for removal?
Flagging an idea indicates that the idea does not meet the standards of the club and you believe it should be removed from the site. Once a threshold has been reached the idea will be removed.
You currently do not have message posting privilages, there are 1 way you can get the privilage.
Apply for or reactivate your full membership
You can apply for full membership by submitting an investment idea of your own. Or if you are in reactivation status, you need to reactivate your full membership.
What is wrong with message, "".